nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.11.2007 | Original Paper

Predictive value of multidrug resistance proteins and cellular drug resistance in childhood relapsed acute lymphoblastic leukemia

verfasst von: Jan Styczynski, Mariusz Wysocki, Robert Debski, Krzysztof Czyzewski, Beata Kolodziej, Beata Rafinska, Malgorzata Kubicka, Sylwia Koltan, Andrzej Koltan, Monika Pogorzala, Andrzej Kurylak, Dorota Olszewska-Slonina, Walentyna Balwierz, Edyta Juraszewska, Maria Wieczorek, Igor Olejnik, Maryna Krawczuk-Rybak, Marta Kuzmicz, Jerzy Kowalczyk, Jolanta Stefaniak, Wanda Badowska, Danuta Sonta-Jakimczyk, Tomasz Szczepanski, Michal Matysiak, Iwona Malinowska, Elzbieta Stanczak

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 11/2007

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Cellular resistance in childhood acute leukemias might be related to profile and function of multidrug resistance proteins and apoptosis regulating proteins. The aims of the study were: (1) analysis of expression of MRP1, PGP1, LRP, BCL-2 and p53 proteins; (2) correlation with ex vivo drug resistance, and (3) analysis of their prognostic impact on clinical outcome in childhood acute lymphoblastic (ALL) and acute myeloid (AML) leukemia.

Methods

Total number of 787 children diagnosed for initial ALL (n = 527), relapsed ALL (n = 104), initial AML (n = 133) and relapsed AML (n = 23) were included into the study. Mean follow-up period was 3.5 years. Drug resistance for up to 30 anticancer agents was performed by the MTT assay. Expression of all proteins was tested by flow cytometry.

Results

Both initial AML and relapsed ALL samples showed higher drug resistance than initial ALL samples. No significant differences were found in drug resistance between initial and relapsed AML samples. The presence of multidrug resistance and apoptosis proteins had no impact on pDFS in iALL and iAML, however strong trend towards adverse prognostic impact of MRP1, PGP and LRP on pDFS in rALL was observed. The same trend was observed for each of analyzed co-expressions of tested multidrug resistance proteins.

Conclusions

The phenomenon of cellular drug resistance in childhood acute leukemias is multifactorial and plays an important role in response to therapy. Expression of MRP1, PGP and LRP proteins, as well as their co-expression play possible role in childhood relapsed ALL.

Arico M, Valsecchi MG, Camitta B, Schrappe M, Chessells J, Baruchel A, Gaynon P, Silverman L, Janka-Schaub G, Kamps W, Pui CH, Masera G (2000) Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 342:998–1006PubMedCrossRef

Borowitz MJ, Pullen DJ, Shuster JJ, Viswanatha D, Montgomery K, Willman CL, Camitta B (2003) Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children’s Oncology Group study. Leukemia 17:1566–1572PubMedCrossRef

Den Boer ML, Pieters R, Kazemier KM, Rottier MM, Zwaan CM, Kaspers GJ, Janka-Schaub G, Henze G, Creutzig U, Scheper RJ, Veerman AJ (1998) Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia. Blood 91:2092–2098

Den Boer ML, Kapaun P, Pieters R, Kazemier KM, Janka-Schaub GE, Veerman AJ (1999a) Myeloid antigen co-expression in childhood acute lymphoblastic leukaemia: relationship with in vitro drug resistance. Br J Haematol 105:876–882CrossRef

Den Boer ML, Pieters R, Kazemier KM, Janka-Schaub GE, Henze G, Creutzig U, Kaspers GJ, Kearns PR, Hall AG, Pearson AD, Veerman AJ (1999b) Different expression of glutathione S-transferase alpha, mu and pi in childhood acute lymphoblastic and myeloid leukaemia. Br J Haematol 104:321–327CrossRef

Den Boer ML, Pieters R, Kazemier KM, Janka-Schaub GE, Henze G, Veerman AJ (1999c) Relationship between the intracellular daunorubicin concentration, expression of major vault protein/lung resistance protein and resistance to anthracyclines in childhood acute lymphoblastic leukemia. Leukemia 13:2023–2030CrossRef

Den Boer ML, Harms DO, Pieters R, Kazemier KM, Gobel U, Korholz D, Graubner U, Haas RJ, Jorch N, Spaar HJ, Kaspers GJ, Kamps WA, Van der Does-Van den Berg A, Van Wering ER, Veerman AJ, Janka-Schaub GE (2003) Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. J Clin Oncol 21:3262–3268CrossRef

Dluzniewska A, Balwierz W, Armata J, Balcerska A, Chybicka A, Kowalczyk J, Matysiak M, Ochocka M, Radwanska U, Rokicka-Milewska R, Sonta-Jakimczyk D, Wachowiak J, Wysocki M (2005) Twenty years of Polish experience with three consecutive protocols for treatment of childhood acute myelogenous leukemia. Leukemia 19:2117–2124PubMedCrossRef

Einsiedel HG, von Stackelberg A, Hartmann R, Fengler R, Schrappe M, Janka-Schaub G, Mann G, Hahlen K, Gobel U, Klingebiel T, Ludwig WD, Henze G (2005) Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Munster Group 87. J Clin Oncol 23:7942–7950PubMedCrossRef

Fleischhack G, Hasan C, Graf N, Mann G, Bode U (1998) IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial. Br J Haematol 102:647–655PubMedCrossRef

Funato T, Harigae H, Abe S, Sasaki T (2004) Assessment of drug resistance in acute myeloid leukemia. Expert Rev Mol Diagn 4:705–713PubMedCrossRef

Ikeda K, Oka M, Yamada Y, Soda H, Fukuda M, Kinoshita A, Tsukamoto K, Noguchi Y, Isomoto H, Takeshima F, Murase K, Kamihira S, Tomonaga M, Kohno S (1999) Adult T-cell leukemia cells over-express the multidrug-resistance-protein (MRP) and lung-resistance-protein (LRP) genes. Int J Cancer 82:599–604PubMedCrossRef

Kakihara T, Tanaka A, Watanabe A, Yamamoto K, Kanto K, Kataoka S, Ogawa A, Asami K, Uchiyama M (1999) Expression of multidrug resistance-related genes does not contribute to risk factors in newly diagnosed childhood acute lymphoblastic leukemia. Pediatr Int 41:641–647PubMed

Kardos G, Zwaan CM, Kaspers GJ, de-Graaf SS, de Bont ES, Postma A, Bokkerink JP, Weening RS, van der Does-van den Berg A, van Wering ER, Korbijn C, Hahlen K (2005) Treatment strategy and results in children treated on three Dutch Childhood Oncology Group acute myeloid leukemia trials. Leukemia 19:2063–2071PubMedCrossRef

Kasimir-Bauer S, Ottinger H, Meusers P, Beelen DW, Brittinger G, Seeber S, Scheulen ME (1998) In acute myeloid leukemia, coexpression of at least two proteins, including P-glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat-shock protein 27, is predictive of the response to induction chemotherapy. Exp Hematol 26:1111–1117PubMed

Kasimir-Bauer S, Beelen D, Flasshove M, Noppeney R, Seeber S, Scheulen ME (2002) Impact of the expression of P glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat shock protein 27 on response to induction therapy and long-term survival in patients with de novo acute myeloid leukemia. Exp Hematol 30:1302–1308PubMedCrossRef

Kaspers GJ, Creutzig U (2005) Pediatric acute myeloid leukemia: international progress and future directions. Leukemia 19:2025–2029PubMedCrossRef

Kaspers GJ, Kardos G, Pieters R, Van Zantwijk CH, Klumper E, Hahlen K, de Waal FC, van Wering ER, Veerman AJ (1994a) Different cellular drug resistance profiles in childhood lymphoblastic and non-lymphoblastic leukemia: a preliminary report. Leukemia 8:1224–1229PubMed

Kaspers GJ, Pieters R, Klumper E, De Waal FC, Veerman AJ (1994b) Glucocorticoid resistance in childhood leukemia. Leuk Lymphoma 13:187–201PubMed

Kaspers GJ, Veerman AJ, Pieters R, Van Zantwijk CH, Smets LA, Van Wering ER, Van Der Does-Van Den Berg A (1997) In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood 90:2723–2729PubMed

Klumper E, Pieters R, Kaspers GJ, Huismans DR, Loonen AH, Rottier MM, van Wering ER, van der Does-van den Berg A, Hahlen K, Creutzig U, Veerman AJ (1995a) In vitro chemosensitivity assessed with the MTT assay in childhood acute non-lymphoblastic leukemia. Leukemia 9:1864–1869PubMed

Klumper E, Pieters R, Veerman AJ, Huismans DR, Loonen AH, Hahlen K, Kaspers GJ, van Wering ER, Hartmann R, Henze G (1995b) In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia. Blood 86:3861–3868PubMed

Kofler R, Schmidt S, Kofler A, Ausserlechner MJ (2003) Resistance to glucocorticoid-induced apoptosis in lymphoblastic leukemia. J Endocrinol 178:19–27PubMedCrossRef

Moricke A, Zimmermann M, Reiter A, Gadner H, Odenwald E, Harbott J, Ludwig WD, Riehm H, Schrappe M (2005) Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95. Klin Padiatr 217:310–320PubMedCrossRef

Ogretmen B, Barredo JC (2000) Safa AR: Increased expression of lung resistance-related protein and multidrug resistance-associated protein messenger RNA in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 22:45–49PubMedCrossRef

Ohno N, Tani A, Chen ZS, Uozumi K, Hanada S, Akiba S, Ren XQ, Furukawa T, Sumizawa T, Arima T, Akiyama SI (2001) Prognostic significance of multidrug resistance protein in adult T-cell leukemia. Clin Cancer Res 7:3120–3126PubMed

Plasschaert S, Vellenga E, De Bont E, Van der Kolk D, Veerman A, Sluiter W, Daenen S, De Vries E, Kamps WA (2003) High functional P-glycoprotein activity is more often present in T-cell acute lymphoblastic leukaemic cells in adults than in children. Leuk Lymphoma 44:85–95PubMedCrossRef

Plasschaert SL, de Bont ES, Boezen M, vander Kolk DM, Daenen SM, Faber KN, Kamps WA, de Vries EG, Vellenga E (2005) Expression of multidrug resistance-associated proteins predicts prognosis in childhood and adult acute lymphoblastic leukemia. Clin Cancer Res 11:8661–8668PubMedCrossRef

Pui CH, Crist WM (1995) Treatment of childhood leukemias. Curr Opin Oncol 7:36–44PubMed

Pui CH, Evans WE 2006) Treatment of acute lymphoblastic leukemia. N Engl J Med 354:166–178PubMedCrossRef

Ramakers-van Woerden NL, Pieters R, Hoelzer D, Slater RM, den Boer ML, Loonen AH, Harbott J, Janka-Schaub GE, Ludwig WD, Ossenkoppele GJ, van Wering ER, Veerman AJ (2002) In vitro drug resistance profile of Philadelphia positive acute lymphoblastic leukemia is heterogeneous and related to age: a report of the Dutch and German Leukemia Study Groups. Med Pediatr Oncol 38:379–386PubMedCrossRef

Ribeiro RC, Razzouk BI, Pounds S, Hijiya N, Pui CH, Rubnitz JE (2005) Successive clinical trials for childhood acute myeloid leukemia at St Jude Children’s Research Hospital, from 1980 to 2000. Leukemia 19:2125–2129PubMedCrossRef

Riehm H, Reiter A, Schrappe M, Berthold F, Dopfer R, Gerein V, Ludwig R, Ritter J, Stollmann B, Henze G (1987) Corticosteroid-dependent reduction of leukocyte count in blood as a prognostic factor in acute lymphoblastic leukemia in childhood (therapy study ALL-BFM 83). Klin Padiatr 199:151–160PubMedCrossRef

Sauerbrey A, Voigt A, Wittig S, Hafer R, Zintl F (2000) Messenger RNA analysis of the multidrug resistance related protein (MRP1) and the lung resistance protein (LRP) in de novo and relapsed childhood acute lymphoblastic leukemia. Leuk Lymphoma 43:875–879CrossRef

Schrappe M, Reiter A, Ludwig WD, Harbott J, Zimmermann M, Hiddemann W, Niemeyer C, Henze G, Feldges A, Zintl F, Kornhuber B, Ritter J, Welte K, Gadner H, Riehm H (2000a) Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood 95:3310–3322PubMed

Schrappe M, Reiter A, Zimmermann M, Harbott J, Ludwig WD, Henze G, Gadner H, Odenwald E, Riehm H (2000b) Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Munster. Leukemia 14:2205–2222PubMedCrossRef

Steinbach D, Lengemann J, Voigt A, Hermann J, Zintl F, Sauerbrey A (2003a) Response to chemotherapy and expression of the genes encoding the multidrug resistance-associated proteins MRP2, MRP3, MRP4, MRP5, and SMRP in childhood acute myeloid leukemia. Clin Cancer Res 9:1083–1086PubMed

Steinbach D, Wittig S, Cario G, Viehmann S, Mueller A, Gruhn B, Haefer R, Zintl F, Sauerbrey A (2003b) The multidrug resistance-associated protein 3 (MRP3) is associated with a poor outcome in childhood ALL and may account for the worse prognosis in male patients and T-cell immunophenotype. Blood 102:4493–4498PubMedCrossRef

Styczynski J, Wysocki M (2004a) Ex vivo drug resistance in childhood acute myeloid leukemia on relapse is not higher than at first diagnosis. Pediatr Blood Cancer 42:195–199PubMedCrossRef

Styczynski J, Wysocki M (2004b) Is the in vitro drug resistance profile the strongest prognostic factor in childhood acute lymphoblastic leukemia? J Clin Oncol 22:963–964PubMedCrossRef

Styczynski J, Wysocki M, Debski R, Juraszewska E, Malinowska I, Stanczak E, Ploszynska A, Stefaniak J, Mazur B, Szczepanski T (2002) Ex vivo drug resistance profile in childhood acute myelogenous leukemia: no drug is more effective in comparison to acute lymphoblastic leukemia. Leuk Lymphoma 43:1843–1848PubMedCrossRef

Styczynski J, Kurylak A, Wysocki M (2005) Cytotoxicity of cortivazol in childhood acute lymphoblastic leukemia. Anticancer Res 25:2253–2258PubMed

Valera ET, Scrideli CA, Queiroz RG, Mori BM, Tone LG (2004) Multiple drug resistance protein (MDR-1), multidrug resistance-related protein (MRP) and lung resistance protein (LRP) gene expression in childhood acute lymphoblastic leukemia. Sao Paulo Med J 122:166–171PubMedCrossRef

van den Heuvel-Eibrink MM, Sonneveld P, Pieters R (2000) The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia. Int J Clin Pharmacol Ther 38:94–110PubMed

van Dongen JJ, Seriu T, Panzer-Grumayer ER, Biondi A, Pongers-Willemse MJ, Corral L, Stolz F, Schrappe M, Masera G, Kamps WA, Gadner H, van Wering ER, Ludwig WD, Basso G, de Bruijn MA, Cazzaniga G, Hettinger K, van der Does-van den Berg A, Hop WC, Riehm H, Bartram CR (1998) Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 352:1731–1738PubMedCrossRef

Wysocki M, Styczynski J, Debski R, Kubicka M, Balwierz W, Juraszewska E, Rokicka-Milewska R, Malinowska I, Matysiak M, Stanczak E, Balcerska A, Ploszynska A, Kowalczyk JR, Stefaniak J, Malek U, Wachowiak J, Mazur B, Sonta-Jakimczyk D, Szczepanski T, Chybicka A, Ras M (2002) Drug resistance profile in childhood acute lymphoblastic leukemia on diagnosis and at relapse with respect to percentile values. Report of Polish Pediatric Leukemia and Lymphoma Study Group. Acta Haematol Pol 33:341–350

Yeoh EJ, Ross ME, Shurtleff SA, Williams WK, Patel D, Mahfouz R, Behm FG, Raimondi SC, Relling MV, Patel A, Cheng C, Campana D, Wilkins D, Zhou X, Li J, Liu H, Pui CH, Evans WE, Naeve C, Wong L, Downing JR (2002) Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 1:133–143PubMedCrossRef

Zhang JB, Sun Y, Dong J, Liu LX, Ning F (2005) [Expression of lung resistance protein and multidrug resistance-associated protein in naive childhood acute leukemia and their clinical significance]. Ai Zheng 24:1015–1017PubMed

Zhao Y, Yu L, Lou F, Wang Q, Pu J, Zhou Q (1999) [The clinical significance of lung resistance-related protein gene (lrp), multidrug resistance-associated protein gene (mrp) and mdr-1/p170 expression in acute leukemia]. Zhonghua Nei Ke Za Zhi38:760–763

Zhao Y, Yu L, Wang Q, Lou F, Pu J (2002) [The relationship between expression of lung resistance-related protein gene or multidrug resistance-associated protein gene and prognosis in newly diagnosed acute leukemia]. Zhonghua Nei Ke Za Zhi 41:183–185PubMed

Zwaan CM (2003) Prognostic factors in AML. In: Toward subgroup-directed therapy in acute myeloid leukemia, Vrije Univeristeit. Amsterdam, pp 24–26

Zwaan CM, Kaspers GJ (2004) Possibilities for tailored and targeted therapy in paediatric acute myeloid leukaemia. Br J Haematol 127:264–279PubMedCrossRef

Zwaan CM, Kaspers GJ, Pieters R, Ramakers-Van Woerden NL, den Boer ML, Wunsche R, Rottier MM, Hahlen K, van Wering ER, Janka-Schaub GE, Creutzig U, Veerman AJ (2000) Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia. Blood 96:2879–2886PubMed

Zwaan CM, Kaspers GJ, Pieters R, Hahlen K, Huismans DR, Zimmermann M, Harbott J, Slater RM, Creutzig U, Veerman AJ (2002) Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities. Blood 100:3352–3360PubMedCrossRef

Zwaan CM, Meshinchi S, Radich JP, Veerman AJ, Huismans DR, Munske L, Podleschny M, Hahlen K, Pieters R, Zimmermann M, Reinhardt D, Harbott J, Creutzig U, Kaspers GJ, Griesinger F (2003) FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. Blood 102:2387–2394PubMedCrossRef

Titel: Predictive value of multidrug resistance proteins and cellular drug resistance in childhood relapsed acute lymphoblastic leukemia
verfasst von: Jan Styczynski
Mariusz Wysocki
Robert Debski
Krzysztof Czyzewski
Beata Kolodziej
Beata Rafinska
Malgorzata Kubicka
Sylwia Koltan
Andrzej Koltan
Monika Pogorzala
Andrzej Kurylak
Dorota Olszewska-Slonina
Walentyna Balwierz
Edyta Juraszewska
Maria Wieczorek
Igor Olejnik
Maryna Krawczuk-Rybak
Marta Kuzmicz
Jerzy Kowalczyk
Jolanta Stefaniak
Wanda Badowska
Danuta Sonta-Jakimczyk
Tomasz Szczepanski
Michal Matysiak
Iwona Malinowska
Elzbieta Stanczak
Publikationsdatum: 01.11.2007
Verlag: Springer-Verlag
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 11/2007
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-007-0274-1

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Predictive value of multidrug resistance proteins and cellular drug resistance in childhood relapsed acute lymphoblastic leukemia

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2007

Anti-vascular endothelial growth factor antibody bevacizumab in conjunction with chemotherapy in metastasising melanoma

Prediction of chronic hepatitis B, liver cirrhosis and hepatocellular carcinoma by SELDI-based serum decision tree classification

Importance of polymorphisms in NF-κB1 and NF-κBIα genes for melanoma risk, clinicopathological features and tumor progression in Swedish melanoma patients